Avalo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Checking your notes…
Item 16. 10-K Summary.
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Avalo Therapeutics, Inc.
/s/ Christopher Sullivan
Christopher Sullivan
Chief Financial Officer
Date: March 23, 2026
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Garry Neil, M.D. | Chief Executive Officer and Director | March 23, 2026 |
| Garry Neil, M.D. | (Principal Executive Officer) | |
| /s/ Christopher Sullivan | Chief Financial Officer | March 23, 2026 |
| Christopher Sullivan | (Principal Financial and Accounting Officer) | |
| /s/ Michael Heffernan | Director and Chairman | March 23, 2026 |
| Michael Heffernan | ||
| /s/ Mitchell Chan | Director | March 23, 2026 |
| Mitchell Chan | ||
| /s/ Jonathan Goldman, M.D. | Director | March 23, 2026 |
| Jonathan Goldman, M.D. | ||
| /s/ Rita Jain, M.D. | Director | March 23, 2026 |
| Rita Jain, M.D. | ||
| /s/ Aaron Kantoff | Director | March 23, 2026 |
| Aaron Kantoff | ||
| /s/ Gilla Kaplan, Ph.D. | Director | March 23, 2026 |
| Gilla Kaplan, Ph.D. | ||
| /s/ Kevin Lind | Director | March 23, 2026 |
| Kevin Lind | ||
| /s/ Samantha Truex | Director | March 23, 2026 |
| Samantha Truex | ||
AVALO THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Mezzanine and Stockholders’ Equity for the years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-8 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.